Reuters logo
BRIEF-ProMIS Neurosciences lead product candidate, PMN310, shows desired target binding profile
2017年10月17日 / 下午12点43分 / 1 个月前

BRIEF-ProMIS Neurosciences lead product candidate, PMN310, shows desired target binding profile

Oct 17 (Reuters) - ProMIS Neurosciences Inc

* ProMIS Neurosciences lead product candidate, PMN310, shows desired target binding profile in direct comparison to other amyloid beta-directed antibodies for alzheimer’s disease Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below